Literature DB >> 26098520

Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.

Amy H Newton1,2, Derek B Danahy1,3, Marcia A Chan4, Stephen H Benedict1.   

Abstract

AIM: It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulatory event on the T-cell surface. This therapy is tested here in mouse emphysema. MATERIALS &
METHODS: Peptides representing contact domains of counter receptors LFA-1 and ICAM-1 were used as blockade therapy in elastase-induced emphysema.
RESULTS: When administered during the first week after disease induction, blockade prevented lung destruction, reduced leukocyte infiltration and inhibited the decrease in T-cell CD4:CD8 ratio, also common in human emphysema.
CONCLUSION: Costimulatory blockade therapy can affect the progress of emphysema.

Entities:  

Keywords:  ICAM-1; T cell; autoimmune therapy; costimulatory blockade; emphysema; selective immunotherapy

Mesh:

Substances:

Year:  2015        PMID: 26098520     DOI: 10.2217/imt.15.31

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  1 in total

1.  Inflammation and endothelial activation in early adulthood are associated with future emphysema: the CARDIA Lung Study.

Authors:  J Michael Wells; Laura A Colangelo; Lakshmi Sivarajan; Bharat Thyagarajan; Mark T Dransfield; Carlos Iribarren; Paul A Reyfman; David R Jacobs; George R Washko; Ravi Kalhan
Journal:  Eur Respir J       Date:  2019-01-17       Impact factor: 16.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.